A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection.
A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection.
复制标题
DOI：
10.1038/s41541-021-00406-4
复制
发表时间：
2021-11-30
期刊：
影响因子：
9.2
通讯作者：
Triccas JA
中科院分区：
文献类型：
--
作者：
Counoupas C;Johansen MD;Stella AO;Nguyen DH;Ferguson AL;Aggarwal A;Bhattacharyya ND;Grey A;Hutchings O;Patel K;Siddiquee R;Stewart EL;Feng CG;Hansbro NG;Palendira U;Steain MC;Saunders BM;Low JKK;Mackay JP;Kelleher AD;Britton WJ;Turville SG;Hansbro PM;Triccas JA
要在全球范围内控制COVID-19，就需要能够广泛获得有效对抗SARS-CoV-2变异体的疫苗。在这份报告中，我们利用现有结核病疫苗卡介苗（BCG）的免疫刺激特性，提供一种具有有效SARS-CoV-2特异性保护性免疫的疫苗接种方案。BCG与稳定的三聚体形式的SARS-CoV-2刺突抗原的组合促进了接种小鼠血液中病毒特异性IgG抗体的快速发展，通过添加明矾进一步增强。该疫苗制剂BCG：CoVac诱导高滴度SARS-CoV-2中和抗体（NAbs）和疫苗特异性T细胞的Th 1偏向性细胞因子释放，这与局部淋巴结中T滤泡辅助细胞的早期出现和疫苗接种后抗原特异性血浆B细胞水平升高相关。K18-hACE 2小鼠接种单剂量BCG：CoVac疫苗后，SARS-CoV-2攻击几乎完全消除了疾病，感染动物的肺部炎症最小，检测不到病毒。加强BCG：用异源疫苗接种CoVac-primed小鼠进一步增加了SARS-CoV-2特异性抗体应答，有效地中和了B.1.1.7和B.1.351 SARS-CoV-2变异体。这些发现证明了基于BCG的疫苗接种在预防全球流行的主要SARS-CoV-2变异方面的潜力。
Global control of COVID-19 requires broadly accessible vaccines that are effective against SARS-CoV-2 variants. In this report, we exploit the immunostimulatory properties of bacille Calmette-Guérin (BCG), the existing tuberculosis vaccine, to deliver a vaccination regimen with potent SARS-CoV-2-specific protective immunity. Combination of BCG with a stabilised, trimeric form of SARS-CoV-2 spike antigen promoted rapid development of virus-specific IgG antibodies in the blood of vaccinated mice, that was further augmented by the addition of alum. This vaccine formulation, BCG:CoVac, induced high-titre SARS-CoV-2 neutralising antibodies (NAbs) and Th1-biased cytokine release by vaccine-specific T cells, which correlated with the early emergence of T follicular helper cells in local lymph nodes and heightened levels of antigen-specific plasma B cells after vaccination. Vaccination of K18-hACE2 mice with a single dose of BCG:CoVac almost completely abrogated disease after SARS-CoV-2 challenge, with minimal inflammation and no detectable virus in the lungs of infected animals. Boosting BCG:CoVac-primed mice with a heterologous vaccine further increased SARS-CoV-2-specific antibody responses, which effectively neutralised B.1.1.7 and B.1.351 SARS-CoV-2 variants of concern. These findings demonstrate the potential for BCG-based vaccination to protect against major SARS-CoV-2 variants circulating globally.
登录
查看更多内容
DOI：
10.1056/nejmoa1714021
发表时间：
2018-07-12
期刊：
The New England journal of medicine
影响因子：
--
作者：
Nemes E;Geldenhuys H;Rozot V;Rutkowski KT;Ratangee F;Bilek N;Mabwe S;Makhethe L;Erasmus M;Toefy A;Mulenga H;Hanekom WA;Self SG;Bekker LG;Ryall R;Gurunathan S;DiazGranados CA;Andersen P;Kromann I;Evans T;Ellis RD;Landry B;Hokey DA;Hopkins R;Ginsberg AM;Scriba TJ;Hatherill M;C-040-404 Study Team
通讯作者：
C-040-404 Study Team
DOI：
10.1136/bmj.n18
发表时间：
2021-01-06
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Iacobucci, Gareth;Mahase, Elisabeth
通讯作者：
Mahase, Elisabeth
影响因子：
2.1
作者：
Nazeri, Saeed;Zakeri, Sedigheh;Djadid, Navid Dinparast
通讯作者：
Djadid, Navid Dinparast
影响因子：
82.9
作者：
Amanat F;Stadlbauer D;Strohmeier S;Nguyen THO;Chromikova V;McMahon M;Jiang K;Arunkumar GA;Jurczyszak D;Polanco J;Bermudez-Gonzalez M;Kleiner G;Aydillo T;Miorin L;Fierer DS;Lugo LA;Kojic EM;Stoever J;Liu STH;Cunningham-Rundles C;Felgner PL;Moran T;García-Sastre A;Caplivski D;Cheng AC;Kedzierska K;Vapalahti O;Hepojoki JM;Simon V;Krammer F
通讯作者：
Krammer F
SARS-COV-2 mRNA疫苗促进与中和抗体产生相关的有效抗原特异性生发中心反应。
影响因子：
32.4
作者：
Lederer K;Castaño D;Gómez Atria D;Oguin TH 3rd;Wang S;Manzoni TB;Muramatsu H;Hogan MJ;Amanat F;Cherubin P;Lundgreen KA;Tam YK;Fan SHY;Eisenlohr LC;Maillard I;Weissman D;Bates P;Krammer F;Sempowski GD;Pardi N;Locci M
通讯作者：
Locci M